Quest Diagnostics
558 hedge funds and large institutions have $11.2B invested in Quest Diagnostics in 2016 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 205 increasing their positions, 197 reducing their positions, and 41 closing their positions.
61% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $23.6M
27% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 41
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
21% more capital invested
Capital invested by funds: $9.29B → $11.2B (+$1.95B)
3.82% more ownership
Funds ownership: 93.85% → 97.66% (+3.8%)
4% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 197
0% more funds holding
Funds holding: 557 → 558 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$685M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$95.2M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$77.8M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$74.6M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$54.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$229M |
| 2 |
Royal London Asset Management
United Kingdom
|
-$188M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$70.2M |
| 4 |
HM
HealthCor Management
New York
|
-$53.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$52.8M |
DGX Hedge Fund Activity: Q2 2016 in Review
558 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2016, worth a combined $11.2B — up 21% from $9.29B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new DGX positions and 41 closed out — a net gain of 11 holders — while 205 added to existing stakes and 197 trimmed.
The largest buyer was Macquarie Group, adding an estimated $685M. The largest seller was T. Rowe Price Associates, cutting an estimated $229M.
- 558 institutional investors held Quest Diagnostics (DGX) as of Q2 2016, up from 557 in Q1 2016.
- Funds reported $11.2B of Quest Diagnostics stock for Q2 2016, up 21% quarter-over-quarter.
- 52 funds opened new Quest Diagnostics positions in Q2 2016 and 41 closed out, a net change of +11 holders.
- The largest Quest Diagnostics buyer in Q2 2016 was Macquarie Group, an estimated $685M added.
- The largest Quest Diagnostics seller in Q2 2016 was T. Rowe Price Associates, an estimated $229M sold.
Based on aggregated 13F filings for Q2 2016.